RxDoctor Payments Data

William Stassen, MD

Gastroenterology · Austin, TXNPI 1548245079

Payments from drug & device makers

$10,551in general payments, 2019–2025

Across 663 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$884
  • Takeda Pharmaceuticals U.S.A., Inc.$760
  • Bristol Myers Squibb$693
  • Pfizer$520
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$10,36798%
  • Education$1842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,551 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$79,808
Medicare patients
335
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide17$20,082
Mesalamine14$7,129
Omeprazole360$4,071
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C30$3,993
Esomeprazole Magnesium31$2,001
Dicyclomine Hcl36$1,025
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg36$822
Pantoprazole Sodium40$668
CholestyramineCholestyramine (With Sugar)23$502
Hydrocortisone24$324
Promethazine Hcl13$293
Ondansetron OdtOndansetron11$229
Propranolol Hcl19$178
Famotidine16$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,529$20,08217 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$1,700$3,99330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →